{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:40:54Z","timestamp":1770896454318,"version":"3.50.1"},"reference-count":124,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.3892\/ijo.2012.1523","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T05:51:49Z","timestamp":1340171509000},"page":"798-804","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism"],"prefix":"10.3892","volume":"41","author":[{"given":"BO-RIM","family":"YI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KELVIN J.","family":"CHOI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SEUNG U.","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KYUNG-CHUL","family":"CHOI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,6,20]]},"reference":[{"key":"key20180107184427_b1-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107184427_b2-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/bcr578","article-title":"Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development","volume":"5","author":"Vincent-Salomon","year":"2003","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b3-ijo-41-03-0798","first-page":"499","article-title":"Infiltrating micropapillary carcinoma of the breast","volume":"12","author":"Middleton","year":"1999","journal-title":"Mod Pathol"},{"key":"key20180107184427_b4-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/1097-0142(20000601)88:11<2553::AID-CNCR18>3.0.CO;2-V","article-title":"Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age","volume":"88","author":"Goldstein","year":"2000","journal-title":"Cancer"},{"key":"key20180107184427_b5-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X","article-title":"Changing incidence rate of invasive lobular breast carcinoma among older women","volume":"88","author":"Li","year":"2000","journal-title":"Cancer"},{"key":"key20180107184427_b6-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.ejca.2006.03.019","article-title":"The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?","volume":"42","author":"Lakhani","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20180107184427_b7-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"key":"key20180107184427_b8-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa065447","article-title":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer","volume":"356","author":"Lehman","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107184427_b9-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1677\/erc.0.0080033","article-title":"The management of ductal carcinoma in situ of the breast","volume":"8","author":"Skinner","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"key20180107184427_b10-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3322\/canjclin.56.1.37","article-title":"Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual","volume":"56","author":"Singletary","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"key20180107184427_b11-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-10-105","article-title":"Long-term survival of cancer patients compared to heart failure and stroke: a systematic review","volume":"10","author":"Askoxylakis","year":"2010","journal-title":"BMC Cancer"},{"key":"key20180107184427_b12-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcb.22610","article-title":"Expression and functions of the repressor element 1 (RE-1)-silencing transcription factor (REST) in breast cancer","volume":"110","author":"Lv","year":"2010","journal-title":"J Cell Biochem"},{"key":"key20180107184427_b13-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2006.10.4703","article-title":"BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model","volume":"25","author":"Vogel","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107184427_b14-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0960-0760(00)00111-4","article-title":"Tumour biology of a breast cancer at least partly reflects the biology of the tissue\/epithelial cell of origin at the time of initiation - a hypothesis","volume":"74","author":"Olsson","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107184427_b15-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"key20180107184427_b16-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2005.09.027","article-title":"The experiences of men with breast cancer in the United Kingdom","volume":"42","author":"Iredale","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20180107184427_b17-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107184427_b18-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0889-8588(05)70058-7","article-title":"The biology of breast cancer","volume":"13","author":"Nass","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20180107184427_b19-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/bcr2836","article-title":"Stress and breast cancer: from epidemiology to molecular biology","volume":"13","author":"Antonova","year":"2010","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b20-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1634\/theoncologist.8-4-326","article-title":"Behavioral risk factors in breast cancer: can risk be modified?","volume":"8","author":"McTiernan","year":"2003","journal-title":"Oncologist"},{"key":"key20180107184427_b21-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00001648-200111000-00005","article-title":"Influence of physical activity in different age and life periods on the risk of breast cancer","volume":"12","author":"Friedenreich","year":"2001","journal-title":"Epidemiology"},{"key":"key20180107184427_b22-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"e7887","DOI":"10.1371\/journal.pone.0007887","article-title":"Profiling critical cancer gene mutations in clinical tumor samples","volume":"4","author":"MacConaill","year":"2009","journal-title":"PLoS One"},{"key":"key20180107184427_b23-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jnci\/92.14.1126","article-title":"Genetic and hormonal risk factors in breast cancer","volume":"92","author":"Martin","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key20180107184427_b24-ijo-41-03-0798","first-page":"845","article-title":"Breast cancer as a mitochondrial disorder (Review)","volume":"21","author":"Plak","year":"2009","journal-title":"Oncol Rep"},{"key":"key20180107184427_b25-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4741.2007.00515.x","article-title":"Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes","volume":"14","author":"Lynch","year":"2008","journal-title":"Breast J"},{"key":"key20180107184427_b26-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.SLA.0000059969.64262.87","article-title":"Rating the risk factors for breast cancer","volume":"237","author":"Singletary","year":"2003","journal-title":"Ann Surg"},{"key":"key20180107184427_b27-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jmg.2006.048173","article-title":"Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations","volume":"44","author":"Kadouri","year":"2007","journal-title":"J Med Genet"},{"key":"key20180107184427_b28-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00439-008-0529-1","article-title":"Hereditary breast cancer: new genetic developments, new therapeutic avenues","volume":"124","author":"Campeau","year":"2008","journal-title":"Hum Genet"},{"key":"key20180107184427_b29-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"key20180107184427_b30-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1038\/sj.onc.1210870","article-title":"BRCA2: a universal recombinase regulator","volume":"26","author":"Thorslund","year":"2007","journal-title":"Oncogene"},{"key":"key20180107184427_b31-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","article-title":"BRCA1 and BRCA2 and the genetics of breast and ovarian cancer","volume":"10","author":"Welcsh","year":"2001","journal-title":"Hum Mol Genet"},{"key":"key20180107184427_b32-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180107184427_b33-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/sj.emboj.7601739","article-title":"Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1","volume":"26","author":"Thorslund","year":"2007","journal-title":"EMBO J"},{"key":"key20180107184427_b34-ijo-41-03-0798","first-page":"119S","article-title":"Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients","volume":"18","author":"Verhoog","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107184427_b35-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0959-8049(00)00098-8","article-title":"Prognosis and clinical presentation of BRCA2-associated breast cancer","volume":"36","author":"Loman","year":"2000","journal-title":"Eur J Cancer"},{"key":"key20180107184427_b36-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.bjc.6605335","article-title":"Mutant p53 mediates survival of breast cancer cells","volume":"101","author":"Lim","year":"2009","journal-title":"Br J Cancer"},{"key":"key20180107184427_b37-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1535-6108(03)00079-5","article-title":"p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis","volume":"3","author":"Bergamaschi","year":"2003","journal-title":"Cancer Cell"},{"key":"key20180107184427_b38-ijo-41-03-0798","first-page":"2505","article-title":"Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer","volume":"61","author":"Geisler","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107184427_b39-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/nar\/26.1.200","article-title":"p53 gene mutation: software and database","volume":"26","author":"Beroud","year":"1998","journal-title":"Nucleic Acids Res"},{"key":"key20180107184427_b40-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107184427_b41-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2008.69","article-title":"Recent advances in p53 research: an interdisciplinary perspective","volume":"16","author":"Olivier","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"key20180107184427_b42-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0168-9525(03)00193-8","article-title":"BRCA1: a scaffold for p53 response?","volume":"19","author":"Hohenstein","year":"2003","journal-title":"Trends Genet"},{"key":"key20180107184427_b43-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-10-1045","article-title":"Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers","volume":"17","author":"Coutant","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107184427_b44-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr738","article-title":"Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer","volume":"6","author":"Yamashita","year":"2004","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b45-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.critrevonc.2004.07.002","article-title":"Mutational spectrum of p53 mutations in primary breast and ovarian tumors","volume":"52","author":"Feki","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107184427_b46-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00432-010-0781-3","article-title":"PTEN mutation spectrum in breast cancers and breast hyperplasia","volume":"136","author":"Yang","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180107184427_b47-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/0008-5472.CAN-10-3263","article-title":"Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution","volume":"71","author":"Wallace","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107184427_b48-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-006-9295-8","article-title":"Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma","volume":"101","author":"Tokunaga","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107184427_b49-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/bcr2204","article-title":"Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells","volume":"10","author":"Marty","year":"2008","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b50-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"key20180107184427_b51-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/annonc\/mdh388","article-title":"Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase\/Akt pathway","volume":"15","author":"DeGraffenried","year":"2004","journal-title":"Ann Oncol"},{"key":"key20180107184427_b52-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cancergencyto.2007.07.017","article-title":"Mutation of the PTEN gene in a human hepatic angiosarcoma","volume":"178","author":"Tate","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"key20180107184427_b53-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/bcr322","article-title":"PTEN deficiency: a role in mammary carcinogenesis","volume":"3","author":"Petrocelli","year":"2001","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b54-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00129039-200409000-00004","article-title":"Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast","volume":"12","author":"Lee","year":"2004","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20180107184427_b55-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1038\/onc.2008.49","article-title":"Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors","volume":"27","author":"Steelman","year":"2008","journal-title":"Oncogene"},{"key":"key20180107184427_b56-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1038\/sj.onc.1203918","article-title":"MMAC1\/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells","volume":"19","author":"Tanaka","year":"2000","journal-title":"Oncogene"},{"key":"key20180107184427_b57-ijo-41-03-0798","first-page":"5275","article-title":"A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase\/Akt in colon carcinoma cells","volume":"61","author":"Bates","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107184427_b58-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/sj.onc.1209877","article-title":"The CHEK2 gene and inherited breast cancer susceptibility","volume":"25","author":"Nevanlinna","year":"2006","journal-title":"Oncogene"},{"key":"key20180107184427_b59-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum Mol Genet"},{"key":"key20180107184427_b60-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.dnarep.2004.04.002","article-title":"PI 3-kinase related kinases: \u2018big\u2019 players in stress-induced signaling pathways","volume":"3","author":"Abraham","year":"2004","journal-title":"DNA Repair"},{"key":"key20180107184427_b61-ijo-41-03-0798","first-page":"8717","article-title":"ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity","volume":"63","author":"Angele","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107184427_b62-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.embor.7400210","article-title":"ATM and ataxia telangiectasia","volume":"5","author":"McKinnon","year":"2004","journal-title":"EMBO Rep"},{"key":"key20180107184427_b63-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/gm12","article-title":"Variants in the ATM gene and breast cancer susceptibility","volume":"1","author":"Milne","year":"2009","journal-title":"Genome Med"},{"key":"key20180107184427_b64-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.1091496","article-title":"Direct activation of the ATM protein kinase by the Mre11\/Rad50\/Nbs1 complex","volume":"304","author":"Lee","year":"2004","journal-title":"Science"},{"key":"key20180107184427_b65-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1086\/421251","article-title":"CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies","volume":"74","author":"Consortium TCBCC-C","year":"2004","journal-title":"Am J Hum Genet"},{"key":"key20180107184427_b66-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.20299","article-title":"CHEK2 variant I157T may be associated with increased breast cancer risk","volume":"111","author":"Kilpivaara","year":"2004","journal-title":"Int J Cancer"},{"key":"key20180107184427_b67-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-007-9838-7","article-title":"Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations","volume":"112","author":"Kleibl","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107184427_b68-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"R184","DOI":"10.1186\/bcr974","article-title":"Breast implants following mastectomy in women with early-stage breast cancer: prevalence and impact on survival","volume":"7","author":"Le","year":"2005","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b69-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00001648-200205001-00008","article-title":"Epidemiology of silicone-gel breast implants","volume":"13","author":"Brown","year":"2002","journal-title":"Epidemiology"},{"key":"key20180107184427_b70-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1111\/j.1075-122X.2006.00209.x","article-title":"Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations","volume":"12","author":"Bese","year":"2006","journal-title":"Breast J"},{"key":"key20180107184427_b71-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180107184427_b72-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107184427_b73-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"R681","DOI":"10.1186\/bcr1274","article-title":"Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines","volume":"7","author":"Zoli","year":"2005","journal-title":"Breast Cancer Res"},{"key":"key20180107184427_b74-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1002\/cncr.26171","article-title":"Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer","volume":"117","author":"McArthur","year":"2011","journal-title":"Cancer"},{"issue":"Suppl 1","key":"key20180107184427_b75-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1023\/A:1024393926965","article-title":"The role of taxanes in the adjuvant treatment of early stage breast cancer","volume":"79","author":"Piccart","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107184427_b76-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1200\/JCO.2003.09.006","article-title":"Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107184427_b77-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nrc2247","article-title":"Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury","volume":"7","author":"Hedley","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20180107184427_b78-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/187152008783497000","article-title":"Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?","volume":"8","author":"Nawa","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180107184427_b79-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H","article-title":"Gene directed enzyme\/prodrug therapy of cancer: historical appraisal and future prospectives","volume":"187","author":"Greco","year":"2001","journal-title":"J Cell Physiol"},{"key":"key20180107184427_b80-ijo-41-03-0798","first-page":"421","article-title":"Gene-directed enzyme prodrug therapy: a current assessment","volume":"6","author":"McKeown","year":"2004","journal-title":"Curr Opin Mol Ther"},{"key":"key20180107184427_b81-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.gt.3301698","article-title":"Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models","volume":"9","author":"Voeks","year":"2002","journal-title":"Gene Ther"},{"key":"key20180107184427_b82-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/78610","article-title":"Gene therapy scores against cancer","volume":"6","author":"Anderson","year":"2000","journal-title":"Nat Med"},{"key":"key20180107184427_b83-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1357-4310(99)01598-1","article-title":"Gene therapy strategies for colon cancer","volume":"6","author":"Chung-Faye","year":"2000","journal-title":"Mol Med Today"},{"key":"key20180107184427_b84-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-05-0393","article-title":"Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2","volume":"65","author":"Schepelmann","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107184427_b85-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/sj.gt.3301557","article-title":"In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase","volume":"8","author":"Chung-Faye","year":"2001","journal-title":"Gene Ther"},{"key":"key20180107184427_b86-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.3748\/wjg.v12.i38.6085","article-title":"Gene therapy of liver cancer","volume":"12","author":"Hernandez-Alcoceba","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key20180107184427_b87-ijo-41-03-0798","first-page":"833","article-title":"Genetically engineered stem cells expressing cytosine deaminase and interferon-\u03b2 migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects","volume":"39","author":"Yi","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107184427_b88-ijo-41-03-0798","first-page":"2853","article-title":"Antitumor therapeutic effects of cytosine deaminase and interferon-\u03b2 against endometrial cancer cells using genetically engineered stem cells in vitro","volume":"31","author":"Yi","year":"2011","journal-title":"Anticancer Res"},{"key":"key20180107184427_b89-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3390\/molecules14114517","article-title":"Bystander or no bystander for gene directed enzyme prodrug therapy","volume":"14","author":"Dachs","year":"2009","journal-title":"Molecules"},{"key":"key20180107184427_b90-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.genom.2.1.177","article-title":"Gene therapy: promises and problems","volume":"2","author":"Pfeifer","year":"2001","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"key20180107184427_b91-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.addr.2011.06.010","article-title":"Mesenchymal stem cells engineered for cancer therapy","volume":"64","author":"Shah","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"key20180107184427_b92-ijo-41-03-0798","first-page":"6847","article-title":"Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene","volume":"63","author":"Ramnaraine","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107184427_b93-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.gt.3301706","article-title":"The potential of 5-fluorocytosine\/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model","volume":"9","author":"Nyati","year":"2002","journal-title":"Gene Ther"},{"key":"key20180107184427_b94-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1107\/S0907444901011064","article-title":"Crystallization and preliminary X-ray analysis of bacterial cytosine deaminase","volume":"57","author":"Ireton","year":"2001","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"key20180107184427_b95-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0969-2126(03)00153-9","article-title":"The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy","volume":"11","author":"Ireton","year":"2003","journal-title":"Structure"},{"key":"key20180107184427_b96-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1155\/S1110724303209098","article-title":"Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)","volume":"2003","author":"Denny","year":"2003","journal-title":"J Biomed Biotechnol"},{"key":"key20180107184427_b97-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1006\/jmbi.2001.5277","article-title":"The structure of Escherichia coli cytosine deaminase","volume":"315","author":"Ireton","year":"2002","journal-title":"J Mol Biol"},{"key":"key20180107184427_b98-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1158\/0008-5472.CAN-09-0615","article-title":"Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo","volume":"69","author":"Fuchita","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107184427_b99-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1349-7006.2009.01485.x","article-title":"Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth","volume":"101","author":"Kim","year":"2010","journal-title":"Cancer Sci"},{"key":"key20180107184427_b100-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2006.12.020","article-title":"Cytosine deaminase\/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro","volume":"67","author":"Chen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180107184427_b101-ijo-41-03-0798","first-page":"773","article-title":"Intratumoral 5-fluorouracil produced by cytosine deaminase\/5-fluorocytosine gene therapy is effective for experimental human glioblastomas","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res"},{"key":"key20180107184427_b102-ijo-41-03-0798","first-page":"1189","article-title":"Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2","volume":"60","author":"Humerickhouse","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107184427_b103-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nsb790","article-title":"Structural insights into CPT-11 activation by mammalian carboxylesterases","volume":"9","author":"Bencharit","year":"2002","journal-title":"Nat Struct Biol"},{"key":"key20180107184427_b104-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X","article-title":"Soft drug design: general principles and recent applications","volume":"20","author":"Bodor","year":"2000","journal-title":"Med Res Rev"},{"key":"key20180107184427_b105-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/mol.60.2.355","article-title":"Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) by carboxylesterases","volume":"60","author":"Wadkins","year":"2001","journal-title":"Mol Pharmacol"},{"key":"key20180107184427_b106-ijo-41-03-0798","first-page":"5078","article-title":"Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase","volume":"61","author":"Wierdl","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107184427_b107-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI119888","article-title":"In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors","volume":"101","author":"Kojima","year":"1998","journal-title":"J Clin Invest"},{"key":"key20180107184427_b108-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1566523023347733","article-title":"Influence of the bystander effect on HSV-tk\/GCV gene therapy. A review","volume":"2","author":"van Dillen","year":"2002","journal-title":"Curr Gene Ther"},{"key":"key20180107184427_b109-ijo-41-03-0798","first-page":"993","article-title":"Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes","volume":"60","author":"Gerolami","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107184427_b110-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1566523033347426","article-title":"Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene\/Ganciclovir system: fifteen years of application","volume":"3","author":"Fillat","year":"2003","journal-title":"Curr Gene Ther"},{"key":"key20180107184427_b111-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-006-9279-x","article-title":"Exogenous wt-p53 enhances the antitumor effect of HSV-TK\/GCV on C6 glioma cells","volume":"82","author":"Huang","year":"2007","journal-title":"J Neurooncol"},{"key":"key20180107184427_b112-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.cgt.7700514","article-title":"Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane","volume":"9","author":"Cowen","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"key20180107184427_b113-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrn1829","article-title":"Gene therapy: can neural stem cells deliver?","volume":"7","author":"Muller","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"key20180107184427_b114-ijo-41-03-0798","first-page":"1249","article-title":"Potential tumor-tropic effect of genetically engineered stem cells expressing suicide enzymes to selectively target invasive cancer in animal models","volume":"31","author":"Kim","year":"2011","journal-title":"Anticancer Res"},{"key":"key20180107184427_b115-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1089\/104303403767740786","article-title":"In vivo tracking of neural progenitor cell migration to glioblastomas","volume":"14","author":"Tang","year":"2003","journal-title":"Hum Gene Ther"},{"key":"key20180107184427_b116-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.mt.6300098","article-title":"Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer","volume":"15","author":"Power","year":"2007","journal-title":"Mol Ther"},{"key":"key20180107184427_b117-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/ijo.2011.1288","article-title":"Stem cells with fused gene expression of cytosine deaminase and interferon-\u03b2 migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use","volume":"40","author":"Kim","year":"2012","journal-title":"Int J Oncol"},{"key":"key20180107184427_b118-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/gt.2008.41","article-title":"Stem and progenitor cell-mediated tumor selective gene therapy","volume":"15","author":"Aboody","year":"2008","journal-title":"Gene Ther"},{"key":"key20180107184427_b119-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1634\/stemcells.2008-0141","article-title":"Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors","volume":"26","author":"Gutova","year":"2008","journal-title":"Stem Cells"},{"key":"key20180107184427_b120-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/CS20040276","article-title":"Neural stem cells and cell replacement therapy: making the right cells","volume":"108","author":"Bithell","year":"2005","journal-title":"Clin Sci"},{"key":"key20180107184427_b121-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1158\/1078-0432.CCR-05-2508","article-title":"Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression","volume":"12","author":"Kim","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107184427_b122-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1098\/rstb.2006.1887","article-title":"Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells","volume":"361","author":"Sohur","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key20180107184427_b123-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-1789.2006.00688.x","article-title":"Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease","volume":"26","author":"Kim","year":"2006","journal-title":"Neuropathology"},{"key":"key20180107184427_b124-ijo-41-03-0798","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2008.290","article-title":"Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases","volume":"17","author":"Joo","year":"2009","journal-title":"Mol Ther"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2012.1523\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T00:36:44Z","timestamp":1561855004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2012.1523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,20]]},"references-count":124,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,6,20]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.3892\/ijo.2012.1523"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2012.1523","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,20]]}}}